Program
afimkibart
Also written as “Afimkibart”, “PF-06480605” and “RO7790121”.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Arthritis, Rheumatoid · Dermatitis, Atopic, led by Hoffmann-La Roche.
Drug pageAfimkibart: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 1814 open or running | phase 3since Sep 6, 2024 | Nov 14, 2013 | Dec 31, 2026phase 2 · NCT05910528 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6631 afimkibart
, phase 3, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Pfizer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 14, 2013.
- Sep 12, 2019Phase 2 study in Moderate to Severe Ulcerative ColitisNCT04090411 · 246 enrolled · United States, Australia, Belgium and more
- Jan 22, 2020Phase 1 study in HealthyNCT04269538 · 16 enrolled · Japan
- Jun 9, 2023Phase 2 study in Crohn DiseaseNCT05910528 · 21 enrolled · United States, Belgium, France and more
- Aug 11, 2024Named afimkibartINNProposed as its International Nonproprietary Name in WHO's List 131 · before, PF-06480605, RO7790121
- Sep 6, 20242 phase 3 studies in Moderately to Severely Active Ulcerative ColitisNCT06589986, NCT06588855
- Feb 6, 20252 phase 3 studies in Moderately to Severely Active Crohns DiseaseNCT06819891, NCT06819878
- Mar 4, 2025Phase 2 study in Dermatitis, AtopicNCT06863961 · 162 enrolled · United States, Brazil, Canada and more
- Mar 18, 2025Phase 1 study in MASHNCT06903065 · 56 enrolled · United States, Mexico, Puerto Rico
- Aug 15, 2025Phase 2 study in Arthritis, RheumatoidNCT07137598 · 160 planned · United States, Argentina, Belgium and more
- Aug 28, 2025Phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT07158242 · 100 planned · United States, Australia, Brazil and more
- Oct 30, 2025Phase 2 study in Dermatitis, AtopicNCT07223697 · 120 enrolled · United States, Brazil, Canada and more
- Dec 19, 2025Phase 3 study in Moderately to Severely Active Crohns DiseaseNCT07298421 · 100 planned · United States, Australia, Brazil and more
- May 27, 2026Phase 2 study in Arthritis, RheumatoidNCT07620392 · 120 planned · United States, Argentina, Brazil and more
- Jun 19, 2026Phase 1 study in Active Ulcerative ColitisNCT07665723 · 25 planned · United States, Belgium, Germany and more
- Sep 10, 2026Phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT07846683 · 350 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Crohn DiseaseNCT05910528
- Jan 30, 2027Primary completion: phase 3 study in Moderately to Severely Active Ulcerative ColitisNCT06589986
- Apr 17, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07137598
- Jul 31, 2027Primary completion: phase 1 study in Active Ulcerative ColitisNCT07665723
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07846683Moderately to Severely Active Ulcerative Colitis · United States | 3 | Recruiting | May 31, 2028 | 350 |
| NCT07665723Active Ulcerative Colitis · United States, Belgium, Germany and more | 1 | Recruiting | Jul 31, 2027 | 25 |
| NCT07620392Arthritis, Rheumatoid · United States, Argentina, Brazil and more | 2 | Recruiting | Jul 8, 2033 | 120 |
| NCT07298421Moderately to Severely Active Crohns Disease · United States, Australia, Brazil and more | 3 | Recruiting | May 31, 2030 | 100 |
| NCT07223697Dermatitis, Atopic · United States, Brazil, Canada and more | 2 | Active, not recruiting | Mar 1, 2033 | 120 |
| NCT07158242Moderately to Severely Active Ulcerative Colitis · United States, Australia, Brazil and more | 3 | Recruiting | Mar 31, 2030 | 100 |
| NCT07137598Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 2 | Recruiting | Apr 17, 2027 | 160 |
| NCT06903065MASH · United States, Mexico, Puerto Rico | 1 | Active, not recruiting | Sep 24, 2026 | 56 |
| NCT06863961Dermatitis, Atopic · United States, Brazil, Canada and more | 2 | Active, not recruiting | Jul 22, 2026 | 162 |
| NCT06819891Moderately to Severely Active Crohns Disease · United States, Argentina, Australia and more | 3 | Recruiting | Dec 31, 2028 | 425 |
| NCT06819878Moderately to Severely Active Crohns Disease · United States, Argentina, Australia and more | 3 | Recruiting | Dec 31, 2028 | 600 |
| NCT06589986Moderately to Severely Active Ulcerative Colitis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 30, 2027 | 400 |
| NCT06588855Moderately to Severely Active Ulcerative Colitis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 29, 2026 | 350 |
| NCT05910528Crohn Disease · United States, Belgium, France and more | 2 | Active, not recruiting | Dec 31, 2026 | 21 |
| NCT04269538Healthy · Japan | 1 | Completed | Nov 11, 2020 | 16 |
| NCT04090411Moderate to Severe Ulcerative Colitis · United States, Australia, Belgium and more | 2 | Completed | Oct 25, 2022 | 246 |
| NCT02840721Colitis, Ulcerative · United States, Belgium, Italy and more | 2 | Completed | May 31, 2018 | 50 |
| NCT01989143Healthy · United States | 1 | Completed | Mar 2015 | 92 |
How it is read
Names in the registry
- “Afimkibart”, 13 entries
- “PF-06480605”, 5 entries
- “RO7790121”, 1 entry
- “Induction- PF-06480605 150 mg SC Q4W”, 1 entry
- “Induction- PF-06480605 450 mg SC Q4W”, 1 entry
Codes read as this program: PF06480605.
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 7 studies
- Crohn Disease, 4 studies
- Arthritis, Rheumatoid, 2 studies
- Dermatitis, Atopic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.